RE: GAP- Insider buying...ChrisparsGood observations as always Chrispars.
Right now investors are in the mode of "how low can I pick this up for".
Investors also knew that there was going to be a significant lull in news in the summer months, and a private placement that needed to take place. The placement has run it's course at 9 cents and it is likely that another one will start hitting the rumor mill in late September.
Dilution continues to play with this stock as people now need to estimate just how many shares will be outstanding by the time we are through phase I and able to attract a significant licensing offer. I am using an estimate of 250,000,000 shares oustanding with an offer of $100,000,000 at that point. That estimate will firm up as we see if Sokoll sticks to his word, and to see what other deals are done in the industry.
I am awaiting to see what cancer they decide to target at the end of this year. Ovarian continues to gain traction, but I still think bladder is the frontrunner....Hence why they are putting so much emphasis on getting
GAP-107B8 fully tested on bladder cancer before they make a decision.
You are right, Jenny and the rest of the doctors continue to accumulate and I think them and others are even more confident in their drug now that it is in a liposomal format, and that Sokoll (who has done this process many times before) is driving it towards trials. Sokoll also mentioned at the AGM that he had some companies to pick from when doing his research on who to work for and he picked GAP for a reason. Pretty risky picking a 15 cent stock at the time to work for wouldn't you think? He knows the potential here.
My leading indicator on when the share price will gain some significant traction will be when Stormont turns the approximate $900,000 that they are owed into shares. I think that time is coming. I also think the time is coming for institutional money to fund this fully through phase I. If I had a guess I would say that the money will come when GAP files their preliminary IND. If Sokoll meets his timeline we could see that mid 2012.
No one doubts the drug, or Sokoll. I want Bob to succeed here, but I need to see him reach out to the current investor base by getting the share price off of the lows.
Otherwise I, (and others) will still be asking the same question before accumulating further "how low can I get this for?"